ArticleFuture oncology (London, England)2026
Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan.
Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chemotherapy After Immune Checkpoint Inhibitor Exposure in Advanced Gastric Cancer: Clinical Evidence and Treatment Sequencing in the ICI Era.Journal of gastrointestinal cancer · 2026Review
- Positioning Zolbetuximab in HER2-Negative Advanced Gastric Cancer: A Practical Framework for Treatment Selection in the ICI Era.Journal of gastrointestinal cancer · 2026Review
- Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan.Future oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe investigated treatment patterns and outcomes in patients with advanced gastric cancer (AGC) after nivolumab first-line therapy approval in Japan in 2021.
methodsThis retrospective study used data from the Medical Data Vision database. Treatment patterns were described. Overall time-to-treatment discontinuation (TTD) from the start of each line was estimated.
resultsAmong 11,276 included patients, 1589 received anti-HER2+chemotherapy (Cx) at any line and regarded as HER2-positive AGC (anti-HER2+Cx group). Among the other, 9687 who presumably had HER2-negative AGC, 5722 received nivolumab+Cx at first-line (Nivo+Cx group), and 3965 received Cx alone at first-line (Cx group). Nivolumab+S-1+oxaliplatin (4,104/11,276; 36.4%) was the most common first-line regimen. The most common second-line and third-line regimens were ramucirumab+paclitaxel (PTX) (or NabPTX) (3092/4345; 71.2%) and nivolumab (490/1712; 28.6%). Median overall TTD from start of first-line therapy was 13.3, 10.5, and 6.8 months in anti-HER2+Cx, Nivo+Cx, and Cx groups. Median overall TTD from start of second-line therapy was 6.2, 3.5, and 4.9 months with ramucirumab combination therapy, ramucirumab monotherapy, and other therapies.
conclusionsAfter first-line nivolumab was introduced for AGC in Japan, treatment patterns remained consistent with Japanese Gastric Cancer Association guidelines. Optimizing sequential therapy, including nivolumab at first-line and ramucirumab combination at second-line, may improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.